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When it Comes to Alopecia Areata – More T Cells Can Be Better!
For several rather common disorders that extend more than skin-deep,
such as alopecia areata (AA) and psoriasis, progress in understanding the
cause and finding effective therapies has been severely hampered by
the lack of suitable animal models. Recent advances by several groups,
however, have led to the establishment of reliable animal models, giving
new hope and excitement to both patients with AA and psoriasis, and
investigative skin biologists trying to understand and thereby prevent
these frequent dermatological disorders. There are several similarities
between psoriasis and AA (although they do not generally coexist in any
given individual), including the principle recognition that these diseases
are most likely not primary skin diseases at all, but rather represent a more
deep-seated disturbance of the immune system that manifests itself in
the skin and hair follicles. Certainly patients with these disorders suffer
emotional pain and suffering beyond the outward cutaneous manifesta-
tions, and researchers are now also forced to try and come to grips with
a systemic foe; namely the pathogenic T cells that are responsible for such
misery. How does such a rogue immune response cause hair-loss in AA
patients or massive keratinocyte thickening in psoriasis?
At first glance, it would seem that agents that tend to reduce the
number and/or activation status of T cells in skin would be beneficial to
our AA and psoriatics, but in the report by Freyschmidt-Paul et al (p. 60),
it appears that increasing the number of different types of T cells in the
skin of mice will lead to better hair growth. These investigators have
developed an important new research tool by utilization of C3H/HeJ
mice that clinically and immunologically resemble human AA. One of
the drawbacks of this model is that it tends to be restricted to only a
minority of aged mice, but this biological glitch may have been solved
by a transplantation approach. It is now possible to graft a punch biopsy
of involved AA skin from an elderly mouse onto a young mouse and
induce AA in the adjacent hair follicles in a more predictable fashion. To
extend their earlier findings, these investigators are now attempting to
validate this animal model from a pharmacological perspective. Using
the same contact sensitizer found to be efficacious in human subjects,
squaric acid dibutylester, they demonstrate that C3H/HeJ mice treated
topically develop an allergic contact dermatitis reaction that has perman-
ent re-growth of hair as one of its side-effects.
Probing the local immune-reaction more extensively, it was observed
that there were quantitative and qualitative changes as well as a spatial
re-distribution of T cells in the AA mice, which re-grow hair following
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the induction of allergic contact dermatitis. The successful induction of
hair growth was characterized immunophenotypically by a decrease in
MHC class I and class II expression by hair follicle epithelium with
minimal change in ICAM-1. Of particular note in this murine system
was that the decreased CD41/CD81 ratio was due to a reduction in
the number of CD81 T cells, whereas in human subjects, resolution was
accompanied by an increased number of CD81 T cells. Clearly more
work needs to be done to decipher the cytokine network present before
and after immunotherapy in both human and murine AA tissue samples.
Despite the difference in the CD81 T cell responses, there are many
striking similarities between AA in man and in this mouse strain. Using
this new animal model in which these mice spontaneously develop AA,
it will now be possible to explore the immunologic as well as the genetic
basis responsible for hair loss.
If immunodermatologists follow the lead of our endocrinology col-
leagues in trying to understand type I diabetes mellitus, having the C3H/
HeJ mice may put us on a par with their NOD mouse models. Just as they
are examining the local relative importanceofCD41 versusCD81 Tcells
in the pancreatic islets that produce disturbances in glucose metabolism
secondary to insulin deficiency, we can now also probe the relative
contribution of these T cell subsets in the skin that produce follicular
disturbances. One very exciting development in the field of immunology
and diabetes has been the discovery that the pathogenic effector T cells
in the tissue site may actually be regulated by a distinctive group of
previously overlooked immunocytes referred to as NK-T cells. In human
subjects, absence or severe reductions in circulating NK-T cells was
correlated to the presence/absence of diabetes amongst identical twins/
triplets, and using NOD mice it now appears that a defect in the immuno-
regulatory network controlled by these NK-T cells may also be operative.
Using the C3H/HeJ mice dermatologists can now determine if NK-T
cells are also capable of regulating the pathogenic T cells in and around
hair follicles, and whether targeting these NK-T cells provides any thera-
peutic results.
Only time and further investigation will determine if NK-T cells are
important in dermatology, but such advances point to new opportunities
for understanding several T-cell mediated skin pathologies. Indeed, look-
ing back at the mouse in Fig 1, it appears that just as one can consider the
glass half-full rather than half-empty, one can regard the partially treated
mouse as half-hairy, rather than half-bald!
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Can We Finally Conclude That Blister Formation in Pemphigus Does Not Require Plasminogen
Activator?
Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are autoimmune
blistering diseases in which the pathogenic antibodies are directed
against desmosomal cadherins. Two theories have been proposed to
explain the mechanism for the loss of cell–cell adhesion, or acantholysis,
induced by pemphigus antibodies: (i) pemphigus antibodies directly
interfere with the adhesive function of desmosomal cadherins; (ii)
pemphigus antibodies induce the secretion of proteases, especially
plasminogen activator (PA), which degrade cell–cell adhesive structures.
PA cleaves and activates the zymogen plasminogen to generate plasmin,
which is the protease proposed to be directly involved in the acantho-
lysis. Both urokinase type PA and tissue type PA have been implicated
in the activation of plasminogen by pemphigus antibodies.
The involvement of proteases in pemphigus blistering is controversial.
Data supporting the protease mechanism include the production of
plasminogen activator by human keratinocytes treated with pemphigus
antibodies, and inhibition of pemphigus antibody-induced acantholysis
by protease inhibitors that inhibit plasminogen activator. Addition of
Is FGF a Life-Saver for Nevus Cells?
While only 1% of individuals are born with a nevus (i.e., congenital
nevus), everyone can attest to the appearance and disappearance of nevi
in their skin over the course of their lifetime from personal observations.
Despite their ubiquitous presence and conspicuousness in adults, very
little is known regarding the molecular pathways responsible for the
growth, locomotion, differentiation, or demize of nevomelanocytes in
the skin. The typical melanocyte spends almost all of its time in the
epidermis, whereas nevomelanocytes (i.e., nevus cells) arise from epi-
dermal melanocytes and initially become manifest as a junctional nevus.
The orderly transition of junctional nevi in teenagers, to compound nevi
in young adults, and then intradermal nevi in most individuals over 40 y
old, is a well-known phenomenon documented by several dermato-
logists. The factors responsible for the initial phenotypic conversion
of an intraepidermal melanocyte to an intraepidermal nevus cell are
unknown, nor is it clear what prompts a collection of intraepidermal
nevomelanocyte to delve into the papillary dermis in such a synchronized
and consistent fashion.
As intraepidermal melanocytes appear to be dependent on certain key
growth factors such as fibroblast growth factor-2 (FGF-2) produced by
keratinocytes, once the nevus cells leave the confines of the epidermis
they may well require a ‘‘life-jacket’’ when they jettison from the epi-
dermis, to ensure their survival in the dermis. Alanko et al (p. 110) begin
to fill the void in our understanding of the biology of benign nevi by
examining the death-defying phenotype of nevus cells. Because most
nevomelanocytes during adulthood spend their time in the dermis, three-
dimensional collagen gels were prepared to simulate in vivo conditions of
the upper dermis, and seeded with nevus cells isolated and propagated
from dermis of human skin samples.
Several observations were made, including the following: first, both
melanocytes and nevus cells maintained in culture express high affinity
receptors for FGF; second, cultured nevus cells produce higher levels of
FGF-2 compared with normal melanocytes; third, while nevus cells
could survive in collagen gels, melanocytes rapidly underwent apoptosis
unless exogenous FGF-2 was produced; fourth, the ability of nevus cells
to resist apoptosis was dependent on their ability to produce FGF-2, as
an inhibitor of FGF-2 (i.e., protamine) rendered nevus cells susceptible
to apoptosis that could be overcome by addition of exogenous FGF-2.
These in vitro findings, together with previous in vivo observations,
plasminogen can also enhance pemphigus antibody-induced blister
formation in organ culture. These studies have been performed
largely in vitro, and are contradicted by in vivo studies. For example,
dexamethasone can largely reduce the activity of PA in neonatal mice
injected with PV sera, but the induction of blisters by PV antibodies
is unaffected. Nevertheless, these studies do not rule out the possibility
that a very low level of PA may be sufficient for pemphigus blistering.
The paper by Mahoney et al (p. 21) strongly refutes the protease
theory of blistering in pemphigus. These authors injected PV and PF
antibodies into neonatal mice with inactivating mutations in either
urokinase type PA or tissue type PA. Blister formation in the PA
knockout mice was identical to that observed in control mice.
Pemphigus sera also induced blisters in mice from urokinase PA and
tissue PA double knockout mice, indicating that one form of PA could
not compensate for the other. These studies convincingly demonstrate
that PA is not required for pemphigus blistering in a well-characterized
in vivo model of pemphigus, and bolster the idea that acantholysis in
pemphigus is due to direct inhibition of cell–cell adhesion.
indicate that nevus cells appear to acquire the capacity to produce their
own FGF-2 in an autocrine fashion, and hence not be as dependent as
melanocytes that require keratinocytes to produce the requisite FGFs in
a paracrine fashion. Hence, the ability to engage this autocrine growth
loop is also linked to an antiapoptotic response. Given the predominant
expression by nevomelanocytes of Bcl-2 over Bcl-x, it is possible that
FGF signaling will impact the Bcl-2 pathway, and hence interrupt the
pro-apoptotic cascade triggered when melanocytes are placed in a 3-
dimensional collagen gel. Some growth factors modulate their effects
through involvement of other growth factors/receptors such as the AKT
pathway, which phosphorylates and thereby inactivates Bad, and hence
mitigate a Bcl-2 binding counterpart. It will be interesting to determine
exactly how FGF-2 is selectively upregulated in nevus cells and the
specific antiapoptotic pathway used in post-FGF receptor stimulation.
Of course it should be noted that this phenomenon of autocrine stimula-
tion in which nevus cells acquire the capacity to not only express high-
affinity FGF receptors, but also produce FGF-2 is like a double-edge
sword.
In several mesenchymal and epithelial-based neoplastic systems, when
a benign cell that expresses the c-met proto-oncogene, also acquires the
capacity to produce hepatocyte growth factor/scatter factor (the ligand
for c-met), a malignant conversion in phenotype frequently occurs. Such
a switch in which the cells that were dependent on a paracrine signal
(i.e., scatter factor produced by fibroblasts) can now become independent
of other cell types, often heralds the onset of malignant transformation.
Thus, it may be that in the melanocytic system, one important molecular
pathway involves a process by which nevus cells that express FGF recep-
tors inappropriately or uncontrollably produce sufficient FGF-2 to facilit-
ate emergence of malignant clones that can proliferate independent from
keratinocytes. This independence and autocrine loop may contribute to
apoptosis resistance, and an aggressive phenotype all too well known to
oncologists treating patients with metastatic melanoma.
In conclusion, it appears that not only may nevus cells use FGF-2 as a
life-preserver, this process may actually represent more closely a self-
inflating raft that could facilitate survival, but also keep premalignant
tumor cells afloat in a sea of hostile local tissue responses, including escape
from the restrictive confines of a paracrine dependence of epidermal
keratinocytes, as well as immunosurveillance mechanisms in the dermis
and at extracutaneous tissue sites.
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Is There a Viral-Mediated Commotion in the Skin of Psoriatics?
Psoriasis is a common disease with prominent cutaneous manifestations
in the skin. In Biblical times and throughout the centuries, psoriasis
was confused with the contagious disorder Leprosy. Currently, psoriasis
is generally regarded as a noninfectious disease that involves the
interplay of both inherited (i.e., genetic) and environmental factors.
Even though a viral etiology was suggested over two decades ago, and
psoriasis was paradoxically found to be increased in HIV-1 infected
patients, only recently has a new role for DNA viruses been implicated
(i.e., human papillomavirus, HPV). Interestingly, another enigmatic
cutaneous disorder exacerbated by AIDS (i.e., Kaposi’s sarcoma) has
also been linked to a DNA virus (albeit a non-HPV member known
as human herpesvirus-8).
Returning to psoriasis, it appears clear that T cells are critically
important for the conversion of symptomless (PN) skin to a psoriatic
plaque (PP skin). Exactly how activated T cells provoke rapid (and
potentially reversible) hyperplasia of epidermal keratinocytes and dermal
microvascular endothelial cells is unclear. Perhaps a greater mystery is
the nature of the stimulus responsible for the activation of T cells.
Weissenborn et al (p. 121) confirm and extend an earlier report that
appeared in the JID by Favre et al (JID 110: 101, 1998), in which
various strains of HPV were identified in psoriatic patients with
a much higher frequency than normal healthy controls or atopic
dermatitis patients.
Using a SCID mouse-human skin xenograft approach, we and others
have demonstrated that pathogenic T cells are indeed present in the
circulation of psoriatic patients, but not normal healthy individuals.
Yet many of our psoriatics have only limited skin disease, pointing to
an additional local activating event. Thus, having circulating pathogenic
T cells is necessary, but not sufficient, for converting the commotion
in the blood to the commotion in the skin that is clinically evident in the
classical appearing erythematous symmetrical and well-circumscribed
plaques of psoriasis. Obviously, there are more questions than answers
at the moment, including the following:
1 Is the stimulus responsible for creating pathogenic T cells in the
circulation, the exact same stimulus in skin? We have recently suggested
that psoriatics have a low frequency of circulating autoreactive T cells
that become expanded by baterial-derived superantigens, such that the
threshold for trafficking of a pathogenic T cell in the skin is reached
at which point the autoreactive skin-seeking T cell triggers keratinocyte
and endothelial cell hyperplasia.
2 Could certain strains of HPV in epidermal keratinocytes be
responsible for provoking a local antiviral immune response? It is
possible that psoriatics are unable to completely or effectively clear the
skin of HPV. In general, however, psoriatic patients appear to have an
enhanced anti-infectious capacity as other bacterial, fungal, and viral
infections are actually relatively infrequent. Indeed, we have recently
suggested that psoriatics may have enhanced innate immunity in the
skin due to the presence of T cells bearing natural killer receptors (i.e.
so-called NK-T cells). We postulated that having an over-active
cutaneous innate immune response may contribute to the frequency
of psoriatic plaques, and be the price we pay as a trade-off to combat
potentially deadly infectious agents (particularly in the preantibiotic
era). Thus the prevalence of psoriasis in populations world-wide may
reflect such a previously overlooked beneficial aspect of the local
immune response.
3 Could the epidermal-based HPV strains produce antigens that
trigger an apparent auto-immune response? If there is a local inflam-
matory and immune-mediated antiviral response by cytotoxic T cells
or NK-T cells, it is possible that disruption of the barrier function may
release glycolipids or peptide-based autoantigens that could perpetuate
the cytokine network producing psoriatic plaques via epitope spreading.
Certain glycolipids may bind CD1d expressed by lesional keratinocytes
or self-peptides may bind MHC class I molecules to further exacerbate
the cellular and cytokine-mediated commotion in the psoriatic plaque.
It should be noted that recently it has been suggested that artery-
clogging plaques in the circulation may be due, in part, to relatively
common bacteria and viral infectious agents. Perhaps not only will
hypertensive patients find benefit from taking antibiotic and antiviral
drugs, but we may well add such anti-infectious drugs to the manage-
ment of psoriatic patients. Obviously much work remains to be done
to more fully determine whether HPV-infection in psoriatic patients
is a primary or secondary event, but using new animal models, it will
be possible to examine this hypothesis by designing experiments that
will establish cause:effect relationships between HPV, keratinocytes,
and immunocytes in the skin.
